Final member of Inogen’s founding team to leave company
Ali Bauerlein, one of Inogen’s co-founders, has stepped down from her post as the company’s CFO, effective immediately on Dec. 13. According to a company news release, Mike Sergesketter has been appointed interim CFO while Inogen look to fill the position. Bauerlein will stay at Inogen in a transitional finance role through the first quarter Read More →
Capsida names new CEO
Capsida Biotherapeutics, a venture-backed Thousand Oaks company developing gene therapy treatments, announced the hiring of a new CEO on Dec. 7. In April, Capsida emerged from “stealth mode” and closed a $140 million series A funding round, one of the largest venture capital raises of the year in the region’s life sciences sector. Capsida is Read More →
Santa Barbara’s Bexson Biomedical wants to kick our opioid habit
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Thousand Oaks health care provider closes $50M funding round
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Clinicas names second-ever CEO
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MannKind reports higher revenue, lower losses in Q3
MannKind Corp. reported a substantial rise in revenue and a shrinking net loss in the third quarter of 2021 on Nov. 9, despite news since the quarter ended that the U.S. Food and Drug Administration will not yet approve a hypertension treatment the company is developing with United Therapeutics. MannKind, a Westlake Village-based biotechnology company Read More →
Atara reports growing losses, but plenty of cash left
Atara Biotherapeutics continued seeing losses in the third quarter of fiscal year 2021, but has enough cash on hand to remain solvent as it awaits news on its tab-cel therapy treatment in early 2022. Atara, a South San Francisco-based immunotherapy based company with major operations in Westlake Village, reported net losses of $84.7 million in Read More →
